Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma

Affiliations

• ¹ Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing.
• ² Tianjin Medical University Cancer Institute and Hospital, Tianjin.
• ³ Sun Yatsen University Cancer Center, Guangzhou.
• ⁴ Harbin Medical University Cancer Hospital, Harbin.
• ⁵ Peking University Third Hospital, Beijing.
• ⁶ Roche (China) Holding Ltd., Shanghai.
• ⁷ Roche RD Center (China) Ltd., Shanghai.
• ⁸ Roche Products Ltd., Welwyn Garden City, UK.
• ⁹ Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing. zhujun@csco.org.cn.